Company intelligence / Profile preview

Berna Biotech AG

Bern, Bern, Switzerlandbernabiotech.co.kr ↗

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Berna Biotech was a leading global vaccine developer and manufacturer with a history dating back to its founding as the Swiss Serum and Vaccine Institute in 1898. It developed over twenty commercialized vaccines targeting major infectious diseases. The company was acquired by Crucell in 2006 but its legacy continues through ongoing programs and collaborations such as those with the Swiss Biotech Center on next-generation COVID‑19 vaccines using advanced VLP technologies. Its Korean affiliate remains active.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: VaccinesMonoclonal antibody
Industry: Biotech

Partnerships

Collaboration with Swiss Biotech Center on COVID‑19 vaccine development.

Beyond the preview

Go deeper on Berna Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berna Biotech AG.